文献速递白血病

TAL1劫持MYCN增强子诱导MYCN表达及T细胞急性淋巴细胞白血病对甲羟戊酸通路的依赖

TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2023-08-17

本研究在T-ALL细胞中鉴定出受TAL1复合物异常激活的进化保守MYCN增强子(enhMYCN),TAL1阳性T-ALL细胞在体外和异种移植模型中依赖MYCN表达维持生存;MYCN驱动甲羟戊酸通路多个基因表达,T-ALL细胞对HMGCR抑制敏感;MYC与MYCN调控相同靶标并相互补偿,MYCN阳性T-ALL细胞呈现对TAL1-MYCN和NOTCH1-MYC通路的双重依赖,提示TAL1-MYCN-HMGCR轴为潜在治疗靶点。

要点

  • T-ALL中TAL1复合物异常激活进化保守的MYCN增强子enhMYCN。
  • TAL1阳性T-ALL细胞在体外和异种移植模型中依赖MYCN表达维持生存。
  • MYCN驱动甲羟戊酸通路基因,T-ALL细胞对HMGCR抑制敏感。

核心结论

  • enhMYCN介导的MYCN表达为人T-ALL细胞所需,TAL1-MYCN-HMGCR轴为T-ALL潜在治疗靶点。

研究设计与样本

  • 研究在T-ALL细胞中鉴定增强子元件,并在体外和异种移植模型中评估MYCN依赖性与HMGCR抑制敏感性。

主要发现

  • TAL1复合物在T-ALL细胞中异常激活进化保守的MYCN增强子enhMYCN。
  • TAL1阳性T-ALL细胞在体外和异种移植模型中高度依赖MYCN表达维持生存。
  • MYCN驱动甲羟戊酸通路多个基因表达,T-ALL细胞对HMGCR抑制敏感。
  • MYC与MYCN调控相同靶标并相互补偿,MYCN阳性T-ALL细胞对TAL1-MYCN和NOTCH1-MYC通路呈双重依赖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A hallmark of T-cell acute lymphoblastic leukemia (T-ALL) is the dysregulated expression of oncogenic transcription factors (TFs), including TAL1, NOTCH1 and MYC. Rewiring of the transcriptional program disrupts the tightly controlled spatiotemporal expression of downstream target genes, thereby contributing to leukemogenesis. In this study, we first identify an evolutionarily conserved enhancer element controlling the MYCN oncogene (named enhMYCN) that is aberrantly activated by the TAL1 complex in T-ALL cells. TAL1-positive T-ALL cells are highly dependent on MYCN expression for their maintenance in vitro and in xenograft models. Interestingly, MYCN drives the expression of multiple genes involved in the mevalonate pathway, and T-ALL cells are sensitive to inhibition of HMG-CoA reductase (HMGCR), a rate-limiting enzyme of this pathway. Importantly, MYC and MYCN regulate the same targets and compensate for each other. Thus, MYCN-positive T-ALL cells display a dual dependence on the TAL1-MYCN and NOTCH1-MYC pathways. Together, our results demonstrate that enhMYCN-mediated MYCN expression is required for human T-ALL cells and implicate the TAL1-MYCN-HMGCR axis as a potential therapeutic target in T-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tan SH, Tan TK, Yokomori R, et al. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia. Leukemia. 2023. PMID: 37591943. doi:10.1038/s41375-023-01993-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。